.Charles Baum, M.D., Ph.D., that looked after Mirati Therapeutics’ $ 5.8 billion sale to Bristol Myers Squibb in 2014, is actually taking the helm of young biotech Terremoto Biosciences.Baum’s “comprehensive experience in medication growth, as well as proven record ahead of time high-impact medications, will contribute,” outward bound CEO Peter Thompson, M.D., said in a July 25 release. Thompson will certainly preserve his chair as board chairperson..Baum, an experienced physician-scientist, was actually the owner, president and also chief executive officer of oncology-focused Mirati. Just before that, he helped establish cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Right now, Baum will definitely function as CEO at Terremoto, a provider developing tiny particles to target disease-causing healthy proteins– like those discovered in harmful tumor cells– making use of covalent bonds. Existing treatments that utilize covalent bonds mostly target the amino acid cysteine. Nevertheless, of the 20 amino acids that make up proteins, cysteine is the least popular.
Terremoto is actually rather targeting one of the necessary amino acids, lysine, which is actually discovered in mostly all healthy proteins.Through targeting amino acid lysine as well as other amino acids, Terremoto hopes to alleviate earlier undruggable diseases and also generate first-in-class medications..The biotech, located in South San Francisco, increased $75 million in series A financing in 2022. A little bit of greater than a year later on, the biotech more than increased that number in a $175 thousand series B.